• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2010; 5(3): e9767.
Published online Mar 22, 2010. doi:  10.1371/journal.pone.0009767
PMCID: PMC2842303

Murine Neural Stem/Progenitor Cells Protect Neurons against Ischemia by HIF-1α–Regulated VEGF Signaling

Rafael Linden, Editor

Abstract

Focal cerebral ischemia following middle cerebral artery occlusion (MCAO) stimulates a robust cytogenic response from the adult subventricular zone (SVZ) that includes massive proliferation of neural stem/progenitor cells (NSPCs) and cellular migration into the injury area. To begin to explore beneficial roles of NSPCs in this response, we investigated the ability of embryonic and postnatal NSPCs to promote neuronal survival under conditions of in vivo and in vitro ischemia. Intracerebral transplantation of NSPCs attenuated neuronal apoptosis in response to focal ischemia induced by transient MCAO, and prevented neuronal cell death of cortical neurons in response to oxygen-glucose deprivation (OGD) in culture. NSPC-mediated neuroprotection was blocked by the pharmacological inhibitors of vascular endothelial growth factor (VEGF), SU1498 and Flt-1Fc. Embryonic and postnatal NSPCs were both intrinsically resistant to brief OGD exposure, and constitutively expressed both hypoxia-inducible factor 1α (HIF-1α) transcription factor and its downstream target, VEGF. Genomic deletion of HIF-1α by Cre-mediated excision of exon 2 in NSPC cultures resulted in >50% reduction of VEGF production and ablation of NSPC-mediated neuroprotection. These findings indicate that NSPCs promote neuronal survival under ischemic conditions via HIF-1α-VEGF signaling pathways and support a role for NSPCs in promotion of neuronal survival following stroke.

Introduction

Two predominant neurogenic regions persist within the adult mammalian brain, located within the subgranular zone (SGZ) of the hippocampal dentate gyrus and the subventricular zone (SVZ) surrounding the lateral ventricles [1][4]. Neural stem/progenitor cells (NSPCs) that reside within these brain regions are mitotically active, self-renewing cells with the potential to differentiate into neurons, oligodendrocytes, or astrocytes [2], [5][7].

Following focal cerebral ischemia, neural stem/progenitor cells (NSPCs) in the SVZ proliferate and migrate to the lesioned site in both rodents and humans [8][14]. Migration of NSPCs and their progeny may be critical for post-ischemic repair, since ablation of progenitor proliferation leads to increased infarct volume [15] and the time course of this migratory response occurs concomitant with partial spontaneous recovery of motor deficits [16], [17]. Although hundreds of thousands of cells emigrate from the SVZ into the injured striatal parenchyma, the number of neuroblasts that survive long-term represents <0.2% of striatal neurons lost to ischemic injury [18]. That such a low number of new neurons contribute significantly to the reconstruction of striatal circuitry seems unlikely. Nevertheless, evidence suggests that SVZ derivatives migrating into the injured striatal parenchyma contribute importantly to the process of endogenous wound healing following ischemic insult, through processes apart or in addition to neuronal replacement [19]. Additional mechanisms include stabilization of nascent vasculature following stroke-induced angiogenesis and/or prevention of progressive neuronal cell loss via release of angiogenic and neurotrophic factors.

Vascular endothelial growth factor (VEGF) is the most well-studied angiogenic factor, but also has been shown to exert direct neurotrophic signaling and to promote adult neurogenesis [20][22]. The most potent inducer of VEGF gene expression is hypoxia [23]. VEGF is transcriptionally regulated by hypoxia inducible factor-1α (HIF-1α), which translocates to the nucleus following hypoxia-induced stabilization, dimerizes with HIF-1β (ARNT), and activates the hypoxia response element (HRE) in the promoter region of the VEGF gene (for review see [24]). VEGF is also regulated by HIF-independent mechanisms including other transcription factors and co-activators [25] (for reviews see [26], [27]), micro-RNAs [28], and inflammatory mediators [29]. In neurons, VEGF mediates its neurotrophic effects via the receptor tyrosine kinase, VEGFR-2 (Flk-1/KDR) [21]. Following stroke, exogenous administration of VEGF has been shown to reduce infarct size and improve neurological performance [30]. These effects are thought to be due to both a direct neurotrophic action of VEGF on neurons and stimulation of angiogenesis for re-establishment of blood flow following ischemic damage. Transgenic mice with VEGF-overexpression also display increased neurogenesis, decreased infarct volume, and improved motor function [31].

Neural stem cells have previously been shown to provide neuroprotection when transplanted into the adult brain in rodent models of stroke [32][34], raising the possibility that the endogenous SVZ response to stroke may also provide neuroprotection of penumbral neurons at risk of delayed cell death. We have previously demonstrated that embryonic neural stem cells secrete diffusible VEGF, which underlies their ability to protect endothelial cells against severe ischemia and promote angiogenesis in ischemic striatum [35]. In the present study, we investigated whether embryonic or postnatal NSPCs also provide neuroprotection against cerebral ischemia utilizing both in vitro and in vivo approaches. Here, we demonstrate that both embryonic and postnatal NSPCs are robustly resistant to oxygen-glucose deprivation (OGD), and provide neuroprotection under ischemic conditions, an effect that is mediated by HIF-1α-regulated release of diffusible VEGF by primary NSPCs. These studies have important implications for both the therapeutic use of exogenous NSPCs in stroke and also suggest a potential neuroprotective role for endogenous NSPCs in adult brain repair.

Results

NSPCs provide neuroprotection against focal ischemia in vivo

To determine whether mouse NSPCs are neuroprotective in our animal model of focal ischemia, we isolated embryonic NSPCs from transgenic mice that express enhanced green fluorescent protein (EGFP) under the β-actin promoter. We have previously demonstrated that these NSPCs fulfill the criteria of multi-potentiality and self-renewal [35]. EGFP-NSPCs were expanded in culture and subsequently transplanted into the right dorsal striatum of adult recipient mice. Control mice received vehicle injections of phosphate buffered saline only. Seventy-two hours following transplantation, recipients were subjected to an ipsilateral transient middle cerebral artery occlusion (MCAO) for 30 minutes, followed by three days of reperfusion. As shown in Figure 1A, MCAO resulted in a robust apoptotic response at three days as assessed by TUNEL labeling of injured striatum in vehicle treated mice. EGFP-NSPC recipients displayed >50% fewer TUNEL+ nuclei compared to vehicle controls (Figure 1B), particularly in the area immediately surrounding the graft and extending out to at least 4.5 mm from the graft border (Figure 1E,F). Conversely, healthy appearing NeuN+ neuronal nuclei were numerous near the graft, whereas control mice displayed widespread loss of NeuN+ cells (Figure 1C,D). These data demonstrate robust NSPC-mediated neuroprotection against focal ischemia in the MCAO model. We previously reported that NSPC-transplant promotes vascularization and proliferation of blood vessels within the ischemic striatum [35], suggesting an effect of NSPCs on the vasculature. Activated neutrophils, as identified by myeloperoxidase (MPO) staining, were not observed in either vehicle- or NSPC-injected striatum, suggesting that NSPC transplantation does not alter the inflammatory response following stroke (Figure S1). To test whether NSPCs have a direct effect on neurons during ischemia, we shifted to an in vitro cell culture system using a well-characterized OGD model [36].

Figure 1
NSPCs protect against 30 minute MCAO.

NSPCs provide neuroprotection against OGD and are intrinsically resistant to in vitro ischemia

We utilized a transwell coculture paradigm to begin to delineate the mechanisms underlying NSPC-mediated neuroprotection. NSPCs and cortical neurons were cultured separately as monocultures or were cocultured in separate compartments of porous transwells (0.4 µm pore size), which allowed for sharing of conditioned media but did not allow cell-cell contact between NSPCs and neurons seeded in the upper vs. lower compartments, respectively. As shown in Figure 2, cortical cultures contained MAP-2+ neurons, with minimal contamination by GFAP+ astrocytes, and NSPC cultures were uniformly immunopositive for the stem cell marker, nestin. Neuronal and NSPC cultures were subjected to control or OGD conditions for 2 hours and assessed for cell viability 24 hr later using an MTT assay. As shown in Figure 2B, cortical cultures underwent approximately 40% cell loss within 24 hr following OGD, as previously described [37], but only ~12% cell loss when cocultured with NSPCs. Importantly, NSPC monocultures were robustly resistant to 2 hour OGD and displayed no significant cell loss at 24 hours (Figure 2C). These data indicate that NSPCs provide robust neuroprotection of cortical neurons in culture via diffusible substance(s), and are themselves resistant to OGD conditions.

Figure 2
NSPCs provide neuroprotection against OGD and are resistant to in vitro ischemia.

Diffusible VEGF is responsible for NSPC-mediated neuroprotection against OGD

HIF-1α is a key mediator of the adaptive cellular response to hypoxia and acts through transcriptional and non-transcriptional pathways to regulate the activities of genes involved in cell survival and angiogenesis, including VEGF. As shown in Figure 3A, NSPC monocultures constitutively expressed HIF-1α and displayed a nearly 3-fold increase in HIF-1α expression measured 24 hr following a 2 hr exposure to OGD. In contrast, HIF-1α was not measurable in neuronal monocultures under nonhypoxic conditions or at 24 hr following a 2 hr OGD exposure (not shown). As shown in Figure 3B, both neuronal and NSPC monocultures constitutively expressed the HIF-1α target gene, VEGF, and released VEGF into the culture media. VEGF release was not statistically different in cortical monocultures following OGD, but was increased 2.5-fold in NSPC monocultures as measured 24 hr following 2 hr exposure to OGD. Culture media from NSPCs was also used to measure the presence of brain-derived neurotrophic factor (BDNF), however BDNF was undetected in both control and OGD-exposed NSPC media (data not shown).

Figure 3
HIF-1α and VEGF expression in eNSPC cultures under control vs. OGD conditions.

To determine whether diffusible VEGF is responsible for NSPC-mediated neuroprotection, neurons in monoculture or in transwell coculture with NSPCs were exposed to OGD in the presence or absence of the VEGFR2 kinase inhibitor, SU1498 (10 µM; Figure 4A) or the VEGF decoy receptor, Flt-1-Fc (1.0 µg/ml; Figure 4B) added at the onset of OGD and present for 24 hr thereafter. As demonstrated in Figure 4A, SU1498 had no effect on neuronal viability under non-ischemic conditions, but completely inhibited the ability of NSPCs to provide neuroprotection against OGD in coculture. Prevention of VEGF-VEGFR interaction at the cell surface with Flt-1-Fc also impaired the neuroprotection provided by cocultured NSPCs (Figure 4B). Dose-response analysis for both SU1498 and Flt-1-Fc showed that neither compound was cytotoxic to neurons in monoculture at the concentration used in this study (Figure S2). Exposure of neuronal cultures to NSPC-conditioned media resulted in significant neuroprotection against OGD, an effect that was also blocked by SU1498 and Flt-1-Fc inhibition of VEGF signaling (Figure 4C). Flt-1-Fc was not cytotoxic to NSPCs, and had no effect on the ability of NSPCs to withstand OGD conditions (Figure S3). These data indicate that NSPC-mediated neuroprotection is mediated by diffusible VEGF and dependent on neuronal VEGFR signaling.

Figure 4
Pharmacological inhibition of VEGF signaling impairs the neuroprotective effects of eNSPCs.

Gene deletion of HIF-1α impairs NSPC-mediated neuroprotection

To determine the extent to which endogenous NSPC HIF-1α governs VEGF expression and NSPC-mediated neuroprotection, eNSPCs were isolated from transgenic mice that harbor loxP sites flanking exon 2 of the HIF-1α gene at both alleles (HIF-1αfl/fl) [38]. HIF-1αwt/wt and HIF-1αfl/fl NSPC cultures were incubated for 24 hr with adenovirus harboring a bacterial Cre-recombinase gene sequence to confer Cre expression (Ad-CMV-Cre). As shown in Figure 5A, transduction of NSPC cultures with Ad-CMV-Cre resulted in excision of HIF-1α exon 2 in HIF-1αfl/fl NSPCs (HIF-1αΔ/Δ), but not in HIF-1αwt/wt NSPCs, as indicated by PCR analysis of genomic DNA isolated 24 hr following removal of Ad-CMV-Cre. HIF-1α transcriptional activity was completely abolished as assessed by the inability of nuclear extract proteins to bind the hypoxia response element (HRE) in HIF-1αΔ/Δ cells, but not in HIF-1αwt/wt cells (Figure 5B). HIF-1α gene deletion in NSPCs also resulted in a 50% reduction of VEGF release by HIF-1αΔ/Δ NSPCs compared to HIF-1αwt/wt NSPCs in response to anoxia (Figure 5C). HIF-1α gene deletion had no effect on NSPC survival at 24 hr following 2 hr OGD (96.8 %±8.5 % vs. 101.6 %±6.7 %, HIF-1αwt/wt vs. HIF-1αΔ/Δ, respectively, ns, n = 4; Figure S4), but abrogated the neuroprotective effects of NSPC conditioned media (Figure 5D). Thus, HIF-1α appears to be necessary for NSPC-mediated neuroprotection since media from HIF-1αΔ/Δ cultures failed to protect neurons from OGD-induced death.

Figure 5
Gene deletion of HIF-1α impairs neuroprotective ability of eNSPC.

Postnatal NSPCs are neuroprotective, resistant to ischemia and constitutively express stabilized HIF-1α and VEGF

To determine whether postnatal NSPCs also confer neuroprotection and are resistance to in vitro ischemia, we isolated NSPCs from postnatal day 28 mouse SVZ and expanded the pNSPCs in culture using the same paradigm as for eNSPCs. As shown in Figure 6 (A and B), pNSPCs constitutively expressed stabilized HIF-1α and VEGF at levels similar to eNSPCs under non-ischemic conditions, with robust induction of both proteins in response to 24 hr anoxia. pNSPCs also displayed resistance to 2 hr OGD exposure (Figure 6C), and media conditioned by pNSPCs provided neuroprotection against 2 hr OGD (Figure 6D).

Figure 6
Postnatal NSPCs are neuroprotective and resistant to ischemia.

Discussion

In this study, we investigated the neuroprotective effects of embryonic and postnatal NSPCs under conditions of ischemia, and the role of HIF-1α-regulated VEGF signaling in this process. We found that exogenous NSPCs protect neurons against focal ischemic injury induced by MCAO in vivo, and protect embryonic cortical neurons against OGD exposure in culture. In contrast to primary cortical neurons, NSPCs display intrinsic resistance to brief 2 hr OGD exposure in culture, and constitutively express stabilized HIF-1α and its downstream target, VEGF. Pharmacological blockade of VEGF signaling in culture impairs neuroprotection, and HIF-1α gene deletion in NSPCs results in both impaired VEGF production and impaired neuroprotection against OGD. These observations provide evidence that NSPCs promote neuronal survival under conditions of ischemia via HIF-1α-regulated VEGF signaling and suggest that NSPCs may play a neuroprotective role following stroke.

VEGF is recognized as both a vasculotrophic factor and a neurotrophic factor. VEGF expression in the brain is downregulated in early postnatal life after formation of the cerebral vasculature is complete, but becomes upregulated in adult brain in response to stroke or mechanical injury [39][41]. Administration of exogenous VEGF following stroke results in reduced neuronal cell death, increased angiogenesis and increased vascular permeability [30], [42], [43] (reviewed in [42], [44], [45]). VEGF also exerts a direct neuroprotective effect against in vitro ischemia, mediated by neuronal VEGFR2 signaling and downstream activation of the phosphatidylinositol 3-kinase (PI3 kinase)/Akt pathway in cultured neurons [46][51]. Our studies suggest that VEGF release by NSPCs underlies in vitro neuroprotection against ischemia, via direct activation of neuronal VEGFR2 receptors, since neuroprotection was abrogated by the presence of the VEGFR2 kinase inhibitor, SU1498, and by the presence of the VEGFR decoy receptor, Flt-1-Fc. In conjunction with our previous report [35], VEGF could have a dual effect in the graft: improved revascularization and direct neuroprotection.

VEGF production by both embryonic and adult NSPCs in culture has previously been reported [35], [52][54]. NSPC expression of VEGF is known to be upregulated in response to hypoxic and metabolic stress [35], [54]. Our present study demonstrates that cortical cultures also release diffusible VEGF under normoxic conditions but do not display increased VEGF production at 24 hr following 2 hr OGD, whereas VEGF release by NSPCs is increased 2–3 fold within 24 hr post-OGD. Although inhibition of VEGFR2 signaling blocks NSPC-mediated neuroprotection, inhibition of VEGFR2 signaling has no impact on the survival of neurons under normoxic conditions, and has no effect on the ability of NSPCs to survive ischemic insult. These observations suggest that increased VEGF production by NSPCs underlies neuronal protection against in vitro ischemia, but does not mediate NSPC resistance to ischemic conditions and is not required for survival of cortical neurons under normoxic conditions.

One of the most potent regulators of VEGF expression is HIF-1α. HIF-1α is primarily regulated at the post-translational level, with protein stability dependent upon pO2. In most mammalian cell types, HIF-1α protein is hydroxylated under normoxic conditions, binds the von Hippel-Lindau (VHL) protein, and is rapidly degraded by the 26S proteosome. Under conditions of hypoxia, HIF-1α is not hydroxylated and rapidly accumulates to enter the nucleus and dimerize with HIF-1β (ARNT), forming the HIF-1 transcriptional complex that regulates target genes through cis-acting hypoxia response elements (HREs). In most cell types HIF-1α mRNA is constitutively transcribed and translated, but the protein only has a half-life of less than 5 minutes under non-hypoxic conditions (for review, see [24], [55]). Our observation that HIF-1α is constitutively stabilized by cultured NSPCs, even at 21% O2, suggests that NSPCs may also utilize a non-oxygen dependent mechanism for maintaining HIF-1α stability and that HIF-1α plays a fundamental role in NSPC homeostasis under both normoxic and hypoxic conditions. Previous studies have demonstrated O2-independent stabilization of HIF-1α by heat shock protein 90 (HSP-90) through binding the PAS domain of HIF-1α [56]. HSP-90 has also been shown to be involved in the regulation of HIF-1α stability in embryonic mesencephalic NSPCs [57].

While the role of constitutive HIF-1α stabilization in NSPCs is not completely understood, HIF-1α is recognized as a multifunctional protein that regulates the expression and activity of multiple genes involved in angiogenesis, glucose metabolism, proliferation and self-renewal, apoptosis, and migration through both transcriptional and non-transcriptional signaling pathways [58]-[61]. Others have shown that upregulation of HIF-1α in neural progenitor cells enhances their ability to survive in vitro and following transplantation [62], as well as provide neuroprotection against ischemia [32]. In addition to VEGF, HIF-1α is a potent inducer of erythropoietin (EPO), which promotes neurogenesis, NSPC proliferation and neuroprotection following ischemia [58], [63][65]. However, neural-specific EPOR knockdown does not increase infarct volume following focal cerebral ischemia and therefore endogenous levels of EPO may not provide neuroprotection following stroke [65]. Conversely, antisense blockade of VEGF in vivo results in an enlargement of infarct volume caused by transient MCAO [66]. In the present study, we found that HIF-1α gene deletion results in >50% reduction of VEGF production and a concomitant impairment of neuroprotective activity in NSPC-conditioned medium. However, these data also indicate that VEGF production is at least partially regulated by HIF-1α-independent mechanisms in NSPCs, since HIF-1α gene deletion did not completely block VEGF production.

We previously demonstrated that embryonic NSPCs protect endothelial cells against ischemia-induced damage and stimulate increased endothelial cell proliferation via HIF-1α-regulated VEGF signaling mechanisms [35]. Here, we extend those studies to demonstrate that NSPCs also provide neuroprotection through similar signaling mechanisms. While neural stem cells were initially recognized as potential therapeutic agents for stroke and neurodegenerative disease based on their potential to replace lost neurons and integrate into host circuitry, our studies support the possibility that the therapeutic potential of neural stem cells may lie predominantly in their ability to promote endogenous brain repair processes. Following stroke, NSPCs and their progeny migrate to the lesioned area and inhibition of this migration leads to an increase in infarct size [15]. Our study reveals that NSPCs may directly protect against ischemic injury through the release of diffusible VEGF. Further studies will require NSPC-targeted gene deletion of VEGF and HIF-1α to delineate the role of endogenous NSPCs in neuroprotection in vivo, as well as their effects on other cell types within the neurovascular niche. While in vitro modeling is crucial to understanding the molecular mechanisms of the interactions between neurons and NSPCs, in vivo studies will account for the ischemic microenvironment.

While our studies suggest that NSPCs themselves are neuroprotective and important for vascular remodeling following stroke, care must be taken with development of therapeutical strategies. Direct NSPC transplantation into the post-ischemic environment may lead to graft overgrowth and tumor formation due to their pluripotency and ability to self-renew [67]. While VEGF infusion may look promising, injection of recombinant human VEGF has been shown to promote blood vessel permeability as well as blood-brain barrier leakage [43]. Thus, elucidating the mechanisms by which NSPCs protect the ischemic penumbra following stroke will provide novel therapeutic strategies for facilitating the contribution of endogenous NSPCs for brain repair.

Methods

Primary cortical neuronal and neural stem/progenitor cultures

Ethics Statement: This study was approved by the University of New Mexico Animal Care and Use Committee and conformed to the NIH Guidelines for use of animals in research. Timed pregnant female mice were sacrificed by isoflurane overdose and the embryos removed by cesarean section. Primary neuronal cultures were established from cerebral cortices of C57BL/6J embryos (The Jackson Laboratory, Bar Harbor, ME, USA) at gestation day 15, using enzymatic dissociation with trypsin as previously described [37]. For immunocytochemistry, 3.9×105 dissociated cells were plated on poly-L-lysine-coated coverslips (0.1 mg/ml; Sigma, St Louis, MO, USA) in 24-well plates. For biochemical procedures, 1.95×106 cells were plated on precoated poly-L-lysine six-well plates (BD Biosciences, San Diego, CA, USA). The cultures were maintained under serum-free conditions in neurobasal medium (Invitrogen Corp., Carlsbad, CA, USA), supplemented with B-27 supplement (2%; Invitrogen Corp.), glutamine (0.5 mM; Sigma), glutamate (25 µM; Sigma), penicillin (100 U/ml) and streptomycin (100 µg/ml; Invitrogen Corp.). At 4 days in vitro (DIV), half of the medium was removed and replaced with fresh medium without glutamate, as indicated by the manufacturer. At 7 DIV, neuronal cultures were used for experimentation. Embryonic neural stem/progenitor cells (eNSPC) were established from whole telencephalon of EGFP-C57BL/6J embryos at gestation day 14 (E14), as described previously [68]. Postnatal NSPCs (pNSPC) were established from postnatal day 28 male EGFP-C57BL/6J mice. NSPCs were plated on pre-coated poly-L-lysine six-well plates (BD Biosciences). Growth factors were added every other day and cells were passaged at least twice prior to use. NSPCs used for coculture were plated on 0.4 µM pore size transwells (BD Biosciences) coated with poly-L-lysine (0.1 mg/mL; Sigma). The cultures were maintained under serum-free conditions in neurobasal medium (Invitrogen Corp.), supplemented with B-27 supplement (2%; Invitrogen Corp.), glutamine (2.0 mM; Sigma), penicillin (100 U/ml; Invitrogen Corp.), streptomycin (100 µg/ml; Invitrogen Corp.), EGF (10 ng/mL; Invitrogen Corp.), and bFGF (10 ng/mL; Invitrogen Corp.). All cultures were maintained in a humidified incubator at 37°C with 5% CO2. The cultures were incubated with the following compounds: SU1498 (70 nM–50 µM; Calbiochem, San Diego, CA, USA), IgG-Fc (5 ng/mL-1 µg/mL; Jackson ImmunoResearch Laboratories, West Grove, PA, USA), and Flt-1-Fc (5 ng/mL-1 µg/mL; R&D Systems, Minneapolis, MN, USA).

Oxygen–glucose deprivation

Oxygen-glucose deprivation (OGD) was performed as previously described [36], [37]. Primary cortical neuronal cultures and/or NSPCs were placed in an anaerobic chamber (Coy Laboratories, Grass Lake, MI, USA) containing a gas mixture of 5% CO2, 5% H2 and 85% N2 (<0.2% O2). Normal culture media was replaced with deoxygenated, glucose-free Earle's balanced salt solution, and the cultures were maintained under glucose-free anaerobic conditions at 37°C for 2 h. OGD was terminated by returning the cultures to normoxic conditions and neurobasal medium supplemented with 2% B-27 supplement, 0.5 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. As a control, sister cultures were placed in Earle's balanced salt solution containing 25 mM glucose (Sigma) for 2 h at 37°C under normoxic (21% O2) conditions and then returned under normoxic conditions to neurobasal medium supplemented with 2% B-27 supplement, 0.5 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin.

Mild transient middle cerebral artery occlusion (MCAO)

Adult male C57BL/6J mice 20–25 g (The Jackson Laboratory) were housed under a 12 h light: 12 h dark cycle with food and water available ad libitum. Mice (20–25 g; n = 20) were anesthetized with 4% isoflurane for induction and maintained on 1.0% isoflurane. The body temperature was maintained at 37°C with a heating pad. Mice were subjected to 30 minutes of transient MCAO as previously described [69]. Briefly, the right common carotid artery was exposed through a midline incision. The internal carotid artery was isolated from external carotid artery which was ligated with 6–0 silk suture. A 2-cm length of 6–0 rounded tip nylon suture was advanced from the common carotid artery (CCA), through the internal carotid artery up to the level of the anterior cerebral artery. The suture was inserted 10 to 11 mm from the bifurcation of CCA to occlude the middle cerebral artery (MCA). After 30 min of MCAO, the suture was slowly withdrawn to allow for reperfusion. Reperfusion time was 3 days post-MCAO. The mice were anesthetized with sodium pentobarbital (150 mg/kg, Fort Dodge Animal Health, Fort Dodge, IA, USA) administered intraperitoneally, and were transcardially perfused first with preperfusing solution (0.01 mg/ml heparin and 1 mg/ml procaine) and subsequently with 4% paraformaldehyde in 0.1 M phosphate buffered saline (PBS). The brains were removed, post-fixed overnight in 4% paraformaldehyde, and cryoprotected with 30% sucrose (w/v) in 0.1 M PBS for 48 hours at 4°C. For immunohistochemical procedures (described below), the brains were sectioned at 30 µm using a sliding microtome (AO Scientific Instruments, Buffalo, NY, USA).

Embryonic NSPC Transplantation

NSPCs isolated from E14 EGFP-expressing transgenic C57BL/6J mouse embryos were expanded in culture as described above and transplanted into 8 week-old C57BL/6J mouse striatum. Mice were anaesthetized with 2% isoflurane inhalation. Stereotaxic injections were performed using Hamilton microsyringe with a 26-gauge blunt needle. Each animal received an injection of 2.5 µl (at the rate of 1 µl/min, and concentration 5×104 cells/µl) of EGFP-NSPCs into the striatum (from bregma: A +1.0 mm, L +2.0 mm, V −2.6 mm). To identify fragmentation of DNA characteristic of apoptosis, TUNEL labeling was performed on paraformaldehyde fixed tissue from 30 minutes MCAO using NeurotacsTM II kit (Trevigen, Inc, Gaithersburg, MD, USA), according to the manufacturer's protocol. Tissue treated with TACs-nuclease™ or without terminal deoxynucleotidyl transferase served as positive and negative controls, respectively. NIH ImageJ software was used to quantify TUNEL+ cells from fluorescent images using Sholl analysis, with concentric rings placed at increasing distances (635 µm apart) around the perimeter of the graft.

Immunohistochemistry

Cultured cells were fixed on coverslips with 4% paraformaldehyde and incubated in monoclonal mouse anti-Nestin (1[ratio]500; Chemicon, Temecula, CA, USA), polyclonal rabbit anti-MAP-2 (1[ratio]500; Chemicon), and/or polyclonal rabbit anti-GFAP (1[ratio]500; Accurate, Westbury, NY, USA). Histological sections (30 µm) were incubated in monoclonal mouse anti-NeuN (1[ratio]1000, Chemicon) or polyclonal rabbit anti-MPO (1[ratio]500, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunofluorescence was visualized using FITC- or Cy3-conjugated secondary antibodies (1[ratio]250; Jackson ImmunoResearch Laboratories). DAPI nuclear stain was used to identify cell bodies of cultured cells (Invitrogen Corp.). Immunofluorescence was analyzed using high-resolution confocal microscopy (Zeiss LSM510, Thornwood, NY, USA) or conventional fluorescence microscopy.

Immunoassays

Soluble VEGF or BDNF were assayed from conditioned media using the Quantikine Mouse Immunoassay for the appropriate protein (R&D Systems). HIF-1α was measured in cell lysates using Surveyor™ IC Human/Mouse Total HIF-1α Immunoassay (R&D Systems). Transcriptional activity of HIF-1α was measured in nuclear extract using the TransAM HIF-1 kit (Active Motif, Carlsbad, CA, USA), substituting the primary antibody for one that recognizes mouse (Novus Biologicals, Littleton, CO, USA). Nuclear extracts used in this assay were isolated using the NE-PER Nuclear and Cytoplasmic Extraction Reagent Kit (Pierce, Rockford, IL, USA). Absorbance for all assays was read using a microplate reader (Dynex Technologies, Chantilly, VA, USA): Quantikine assays were read at 450 nm with background subtraction of 570 nm; TransAM assay was read at 450 nm with a background subtraction of 630 nm.

MTT cell viability assay

Cell viability was assessed using methylthiazolyldiphenyl-tetrazolium bromide (MTT) dissolved in PBS (0.5 mg/mL; Sigma). Cultures were incubated with MTT at 37°C for 4 hr. Formazan crystals were solubilized using 1[ratio]1 ethanol:DMSO solution. Absorbance was measured at 570 nm with a background subtraction of 630 nm.

HIF-1α gene deletion from NSPCs

NSPCs were isolated from embryonic day 14 transgenic mice containing loxP-flanked exon 2 of the HIF-1α gene (HIF-1αfl/fl) [38] that were crossed to the C57BL/6J background (The Jackson Laboratory). NSPCs were passaged twice prior to 48 hr treatment with an adenovirus expressing Cre-recombinase (Ad-CMV-Cre; Vector Biolabs, Philadelphia, PA, USA) at 50 MOI (multiplicity of infection). This method recombines the DNA between the two loxP sites to excise the intervening sequence. Twenty-four hours after infection, NSPCs were passaged twice more before used in experiments. To confirm deletion of exon 2 of the HIF-1α gene, DNA was isolated and efficiency of cre-recombination was detected with PCR using forward primer 5′- TGT TAA ATA AAA GCT TGG AC -3′ and reverse primer 5′- GCA GTT AAG AGC ACT AGT TG -3′ [70]. Successful DNA recombination yields HIF-1α gene-deleted NSPCs (HIF-1αΔ/Δ), as indicated by the loss of the 1200 bp band amplification product and appearance of a 250 bp band. Experiments using HIF-1αΔ/Δ eNSPCs were compared to wild-type C57BL/6J eNSPCs treated similarly with Ad-CMV-Cre.

Statistical Analysis

Data are expressed as means ± S.E.M. Significant differences between means were determined by student's t-test or analysis of variance (ANOVA) with Tukey multiple comparisons post hoc analysis using Prism software (Graphpad Software, San Diego, CA, USA). P values < 0.05 are considered statistically significant.

Supporting Information

Figure S1

Myeloperoxidase (MPO) staining for activated neutrophils. (A–D) Myeloperoxidase (MPO) staining of coronal histological sections through the ischemic striatum 3 days following MCAO. Mice received intrastriatal injections of exogenous EGFP+NSPCs (A–C) or PBS (D) 72 hr prior to MCAO. Scale bar: 10 µm.

(4.33 MB TIF)

Figure S2

Dose-response of neurons to SU1498 and Flt-1-Fc. Neurons were exposed to increasing concentrations of the VEGFR2 inhibitor SU1498 (A) or the decoy VEGFR1 Flt-1-Fc (B). SU1498 was cytotoxic at concentrations of 50 and 100 µM, but not at 10 µM which was the dose used in our experiments (A). A toxic dose of Flt-1-Fc was not determined (B).

(0.22 MB TIF)

Figure S3

NSPC response to inhibition of autocrine VEGF. Embryonic NSPCs were exposed to the VEGFR1 decoy Flt-1-Fc (1 µg/mL). Flt-1-Fc did not impair the viability of eNSPCs, and did not impair their ability to survive OGD.

(0.16 MB TIF)

Figure S4

NSPC viability in response to 2 hr OGD. Deletion of exon 2 of the HIF-1α gene did not impair eNSPC ability to survive 2 hr OGD, as compared to wild-type eNSPCs.

(0.14 MB TIF)

Acknowledgments

Confocal images were generated using the University of New Mexico Cancer Center Fluorescence Microscopy Facility, supported as detailed at http://hsc.unm.edu/crtc/microscopy/facility.html. The authors thank Tamara Roitbak, Patrick B. Ventura and Kelsey Thomas for outstanding technical assistance.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by grants from the American Heart Association (www.americanheart.org), 0810071Z (KMH) and 09GRNT2290178 (LAC), and Dedicated Health Research Funds from the University of New Mexico School of Medicine (http://hsc.unm.edu/som/), C-2310-RAC/Bridge (LAC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4:1313–1317. [PubMed]
2. Gage FH. Mammalian neural stem cells. Science. 2000;287:1433–1438. [PubMed]
3. Doetsch F. A niche for adult neural stem cells. Curr Opin Genet Dev. 2003;13:543–550. [PubMed]
4. Alvarez-Buylla A, Lim DA. For the long run: maintaining germinal niches in the adult brain. Neuron. 2004;41:683–686. [PubMed]
5. McKay R. Stem cells in the central nervous system. Science. 1997;276:66–71. [PubMed]
6. Temple S. The development of neural stem cells. Nature. 2001;414:112–117. [PubMed]
7. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, et al. A stem cell molecular signature. Science. 2002;298:601–604. [PubMed]
8. Jin K, Minami M, Lan JQ, Mao XO, Batteur S, et al. Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. Proc Natl Acad Sci U S A. 2001;98:4710–4715. [PMC free article] [PubMed]
9. Jin K, Wang X, Xie L, Mao XO, Zhu W, et al. Evidence for stroke-induced neurogenesis in the human brain. Proc Natl Acad Sci U S A. 2006;103:13198–13202. [PMC free article] [PubMed]
10. Zhang RL, Zhang ZG, Zhang L, Chopp M. Proliferation and differentiation of progenitor cells in the cortex and the subventricular zone in the adult rat after focal cerebral ischemia. Neuroscience. 2001;105:33–41. [PubMed]
11. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med. 2002;8:963–970. [PubMed]
12. Parent JM, Vexler ZS, Gong C, Derugin N, Ferriero DM. Rat forebrain neurogenesis and striatal neuron replacement after focal stroke. Ann Neurol. 2002;52:802–813. [PubMed]
13. Iwai M, Sato K, Kamada H, Omori N, Nagano I, et al. Temporal profile of stem cell division, migration, and differentiation from subventricular zone to olfactory bulb after transient forebrain ischemia in gerbils. J Cereb Blood Flow Metab. 2003;23:331–341. [PubMed]
14. Yamashita T, Ninomiya M, Hernandez Acosta P, Garcia-Verdugo JM, Sunabori T, et al. Subventricular zone-derived neuroblasts migrate and differentiate into mature neurons in the post-stroke adult striatum. J Neurosci. 2006;26:6627–6636. [PubMed]
15. Maysami S, Lan JQ, Minami M, Simon RP. Proliferating progenitor cells: a required cellular element for induction of ischemic tolerance in the brain. J Cereb Blood Flow Metab. 2008;28:1104–1113. [PubMed]
16. Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn KR, et al. Transplantation of cultured human neuronal cells for patients with stroke. Neurology. 2000;55:565–569. [PubMed]
17. Zhang RL, Zhang ZG, Chopp M. Neurogenesis in the adult ischemic brain: generation, migration, survival, and restorative therapy. Neuroscientist. 2005;11:408–416. [PubMed]
18. Kokaia Z, Thored P, Arvidsson A, Lindvall O. Regulation of stroke-induced neurogenesis in adult brain--recent scientific progress. Cereb Cortex. 2006;16(Suppl 1):i162–167. [PubMed]
19. Burns TC, Verfaillie CM, Low WC. Stem cells for ischemic brain injury: a critical review. J Comp Neurol. 2009;515:125–144. [PubMed]
20. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84:1470–1478. [PMC free article] [PubMed]
21. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci U S A. 2002;99:11946–11950. [PMC free article] [PubMed]
22. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581–611. [PubMed]
23. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843–845. [PubMed]
24. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–732. [PubMed]
25. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature. 2008;451:1008–1012. [PubMed]
26. Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res. 2007;13:5670–5674. [PubMed]
27. Birk DM, Barbato J, Mureebe L, Chaer RA. Current insights on the biology and clinical aspects of VEGF regulation. Vasc Endovascular Surg. 2008;42:517–530. [PubMed]
28. Hua Z, Lv Q, Ye W, Wong CK, Cai G, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One. 2006;1:e116. [PMC free article] [PubMed]
29. McColl BK, Stacker SA, Achen MG. Molecular regulation of the VEGF family -- inducers of angiogenesis and lymphangiogenesis. Apmis. 2004;112:463–480. [PubMed]
30. Sun Y, Jin K, Xie L, Childs J, Mao XO, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest. 2003;111:1843–1851. [PMC free article] [PubMed]
31. Wang Y, Jin K, Mao XO, Xie L, Banwait S, et al. VEGF-overexpressing transgenic mice show enhanced post-ischemic neurogenesis and neuromigration. J Neurosci Res. 2007;85:740–747. [PubMed]
32. Chu K, Jung KH, Kim SJ, Lee ST, Kim J, et al. Transplantation of human neural stem cells protect against ischemia in a preventive mode via hypoxia-inducible factor-1alpha stabilization in the host brain. Brain Res. 2008;1207:182–192. [PubMed]
33. Jin K, Mao X, Xie L, Galvan V, Lai B, et al. Transplantation of human neural precursor cells in Matrigel scaffolding improves outcome from focal cerebral ischemia after delayed postischemic treatment in rats. J Cereb Blood Flow Metab. 2010;30:534–544. [PMC free article] [PubMed]
34. Hayashi J, Takagi Y, Fukuda H, Imazato T, Nishimura M, et al. Primate embryonic stem cell-derived neuronal progenitors transplanted into ischemic brain. J Cereb Blood Flow Metab. 2006;26:906–914. [PubMed]
35. Roitbak T, Li L, Cunningham LA. Neural stem/progenitor cells promote endothelial cell morphogenesis and protect endothelial cells against ischemia via HIF-1alpha-regulated VEGF signaling. J Cereb Blood Flow Metab. 2008;28:1530–1542. [PMC free article] [PubMed]
36. Plesnila N, Zinkel S, Le DA, Amin-Hanjani S, Wu Y, et al. BID mediates neuronal cell death after oxygen/glucose deprivation and focal cerebral ischemia. Proc Natl Acad Sci U S A. 2001;98:15318–15323. [PMC free article] [PubMed]
37. Wetzel M, Li L, Harms KM, Roitbak T, Ventura PB, et al. Tissue inhibitor of metalloproteinases-3 facilitates Fas-mediated neuronal cell death following mild ischemia. Cell Death Differ. 2008;15:143–151. [PubMed]
38. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 2000;60:4010–4015. [PubMed]
39. Kovacs Z, Ikezaki K, Samoto K, Inamura T, Fukui M. VEGF and flt. Expression time kinetics in rat brain infarct. Stroke. 1996;27:1865–1873. [PubMed]
40. Krum JM, Rosenstein JM. VEGF mRNA and its receptor flt-1 are expressed in reactive astrocytes following neural grafting and tumor cell implantation in the adult CNS. Exp Neurol. 1998;154:57–65. [PubMed]
41. Marti HH, Risau W. Angiogenesis in ischemic disease. Thromb Haemost. 1999;82(Suppl 1):44–52. [PubMed]
42. Greenberg DA, Jin K. From angiogenesis to neuropathology. Nature. 2005;438:954–959. [PubMed]
43. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest. 2000;106:829–838. [PMC free article] [PubMed]
44. Hansen TM, Moss AJ, Brindle NP. Vascular endothelial growth factor and angiopoietins in neurovascular regeneration and protection following stroke. Curr Neurovasc Res. 2008;5:236–245. [PubMed]
45. Carmeliet P, Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol. 2002;13:39–53. [PubMed]
46. Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, et al. TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc Natl Acad Sci U S A. 2008;105:6185–6190. [PMC free article] [PubMed]
47. Ogunshola OO, Antic A, Donoghue MJ, Fan SY, Kim H, et al. Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system. J Biol Chem. 2002;277:11410–11415. [PubMed]
48. Rosenstein JM, Mani N, Khaibullina A, Krum JM. Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons. J Neurosci. 2003;23:11036–11044. [PubMed]
49. Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A. 2000;97:10242–10247. [PMC free article] [PubMed]
50. Kilic E, Kilic U, Wang Y, Bassetti CL, Marti HH, et al. The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. Faseb J. 2006;20:1185–1187. [PubMed]
51. Jin K, Mao XO, Batteur SP, McEachron E, Leahy A, et al. Caspase-3 and the regulation of hypoxic neuronal death by vascular endothelial growth factor. Neuroscience. 2001;108:351–358. [PubMed]
52. Teng H, Zhang ZG, Wang L, Zhang RL, Zhang L, et al. Coupling of angiogenesis and neurogenesis in cultured endothelial cells and neural progenitor cells after stroke. J Cereb Blood Flow Metab. 2008;28:764–771. [PMC free article] [PubMed]
53. Wang L, Chopp M, Gregg SR, Zhang RL, Teng H, et al. Neural progenitor cells treated with EPO induce angiogenesis through the production of VEGF. J Cereb Blood Flow Metab. 2008;28:1361–1368. [PMC free article] [PubMed]
54. Madhavan L, Ourednik V, Ourednik J. Neural stem/progenitor cells initiate the formation of cellular networks that provide neuroprotection by growth factor-modulated antioxidant expression. Stem Cells. 2008;26:254–265. [PubMed]
55. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ. 2008;15:621–627. [PubMed]
56. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem. 2002;277:29936–29944. [PubMed]
57. Xiong L, Zhao T, Huang X, Liu ZH, Zhao H, et al. Heat shock protein 90 is involved in regulation of hypoxia-driven proliferation of embryonic neural stem/progenitor cells. Cell Stress Chaperones. 2009;14:183–192. [PMC free article] [PubMed]
58. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab. 1999;19:643–651. [PubMed]
59. Chen N, Chen X, Huang R, Zeng H, Gong J, et al. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. J Biol Chem. 2009;284:10004–10012. [PMC free article] [PubMed]
60. Bergeron M, Yu AY, Solway KE, Semenza GL, Sharp FR. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur J Neurosci. 1999;11:4159–4170. [PubMed]
61. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell. 2005;9:617–628. [PubMed]
62. Theus MH, Wei L, Cui L, Francis K, Hu X, et al. In vitro hypoxic preconditioning of embryonic stem cells as a strategy of promoting cell survival and functional benefits after transplantation into the ischemic rat brain. Exp Neurol. 2008;210:656–670. [PubMed]
63. Chen ZY, Asavaritikrai P, Prchal JT, Noguchi CT. Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J Biol Chem. 2007;282:25875–25883. [PubMed]
64. Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci. 2001;21:9733–9743. [PubMed]
65. Tsai PT, Ohab JJ, Kertesz N, Groszer M, Matter C, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci. 2006;26:1269–1274. [PubMed]
66. Yang ZJ, Bao WL, Qiu MH, Zhang LM, Lu SD, et al. Role of vascular endothelial growth factor in neuronal DNA damage and repair in rat brain following a transient cerebral ischemia. J Neurosci Res. 2002;70:140–149. [PubMed]
67. Seminatore C, Polentes J, Ellman D, Kozubenko N, Itier V, et al. The postischemic environment differentially impacts teratoma or tumor formation after transplantation of human embryonic stem cell-derived neural progenitors. Stroke. 2010;41:153–159. [PubMed]
68. Ray J, Peterson DA, Schinstine M, Gage FH. Proliferation, differentiation, and long-term culture of primary hippocampal neurons. Proc Natl Acad Sci U S A. 1993;90:3602–3606. [PMC free article] [PubMed]
69. Kokovay E, Li L, Cunningham LA. Angiogenic recruitment of pericytes from bone marrow after stroke. J Cereb Blood Flow Metab. 2006;26:545–555. [PubMed]
70. Milosevic J, Maisel M, Wegner F, Leuchtenberger J, Wenger RH, et al. Lack of hypoxia-inducible factor-1 alpha impairs midbrain neural precursor cells involving vascular endothelial growth factor signaling. J Neurosci. 2007;27:412–421. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...